Patents by Inventor Tedd D. Elich

Tedd D. Elich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11932862
    Abstract: Polynucleotides comprising genetic regulatory elements, as well as constructs, host cells, and transgenic organisms comprising the same are described. The polynucleotides can control the expression of an operably linked gene in a host cell or organism, such as a plant cell or a plant. Methods of using the polynucleotide to control the expression of an operably linked gene of interest in a plant or plant cell are further provided.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: March 19, 2024
    Assignee: Monsanto Technology LLC
    Inventors: Ian W. Davis, Tedd D. Elich
  • Patent number: 11926843
    Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: March 12, 2024
    Assignee: LifeEDIT Therapeutics, Inc.
    Inventors: Alexandra Briner Crawley, Rodolphe Barrangou, Tyson D. Bowen, Michael Coyle, Tedd D. Elich
  • Publication number: 20240026384
    Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.
    Type: Application
    Filed: August 10, 2023
    Publication date: January 25, 2024
    Applicant: LifeEDIT Therapeutics, Inc.
    Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
  • Patent number: 11859181
    Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.
    Type: Grant
    Filed: August 31, 2022
    Date of Patent: January 2, 2024
    Assignee: LIFEEDIT THERAPEUTICS, INC.
    Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
  • Publication number: 20230272398
    Abstract: Compositions and methods for binding to a target sequence of interest are provided. Compositions include fusion proteins between DNA binding proteins or protein domains and nucleic acid modifying proteins or protein domains. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, deaminases, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs. Also provided are deaminases which may be fused to a DNA-binding polypeptide and may be useful for gene editing.
    Type: Application
    Filed: May 12, 2023
    Publication date: August 31, 2023
    Applicant: LifeEDIT Therapeutics, Inc.
    Inventors: Tyson D. Bowen, Alexandra Briner Crawley, Tedd D. Elich, Mark Moore, Michael Lassner
  • Publication number: 20230257742
    Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.
    Type: Application
    Filed: August 31, 2022
    Publication date: August 17, 2023
    Applicant: LifeEDIT Therapeutics, Inc.
    Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
  • Publication number: 20230235360
    Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.
    Type: Application
    Filed: September 1, 2022
    Publication date: July 27, 2023
    Applicant: LifeEDIT Therapeutics, Inc.
    Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
  • Publication number: 20230203463
    Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, detecting a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.
    Type: Application
    Filed: December 28, 2020
    Publication date: June 29, 2023
    Applicant: LifeEDIT Therapeutics, Inc.
    Inventors: Alexandra Briner Crawley, Philip Borden, Tyson D. Bowen, Michael Coyle, Madison R. Rackear, Tedd D. Elich
  • Publication number: 20230175018
    Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.
    Type: Application
    Filed: June 28, 2022
    Publication date: June 8, 2023
    Applicant: LifeEDIT Therapeutics, Inc.
    Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
  • Publication number: 20230002747
    Abstract: Compositions and methods comprising novel deaminase polypeptides for targeted editing of nucleic acids are provided. Compositions comprise deaminase polypeptides. Also provided are fusion proteins comprising a DNA-binding polypeptide and a deaminase of the invention. The fusion proteins include RNA-guided nucleases fused to deaminases, optionally in complex with guide RNAs. Compositions also include nucleic acid molecules encoding the deaminases or the fusion proteins. Vectors and host cells comprising the nucleic acid molecules encoding the deaminases or the fusion proteins are also provided.
    Type: Application
    Filed: September 1, 2022
    Publication date: January 5, 2023
    Applicant: LifeEDIT Therapeutics, Inc.
    Inventors: Tyson D. Bowen, Alexandra Briner Crawley, Tedd D. Elich
  • Publication number: 20220364074
    Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs. Methods and kits for detecting a target DNA sequence are also provided.
    Type: Application
    Filed: August 11, 2020
    Publication date: November 17, 2022
    Applicant: LIFEEDIT THERAPEUTICS, INC.
    Inventors: Tyson D. Bowen, Alexandra Briner Crawley, Tedd D. Elich, Michael Coyle
  • Publication number: 20220348894
    Abstract: Compositions and methods comprising novel deaminase polypeptides for targeted editing of nucleic acids are provided. Compositions comprise deaminase polypeptides. Also provided are fusion proteins comprising a DNA-binding polypeptide and a deaminase of the invention. The fusion proteins include RNA-guided nucleases fused to deaminases, optionally in complex with guide RNAs. Compositions also include nucleic acid molecules encoding the deaminases or the fusion proteins. Vectors and host cells comprising the nucleic acid molecules encoding the deaminases or the fusion proteins are also provided.
    Type: Application
    Filed: June 28, 2022
    Publication date: November 3, 2022
    Applicant: LifeEDIT Therapeutics, Inc.
    Inventors: Tyson D. Bowen, Alexandra Briner Crawley, Tedd D. Elich
  • Patent number: 11377663
    Abstract: Polynucleotides comprising genetic regulatory elements, as well as constructs, host cells, and transgenic organisms comprising the same are described. The polynucleotides can control the expression of an operably linked gene in a host cell or organism, such as a plant cell or a plant. Methods of using the polynucleotide to control the expression of an operably linked gene of interest in a plant or plant cell are further provided.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: July 5, 2022
    Assignee: Monsanto Technology LLC
    Inventors: Ian W. Davis, Tedd D. Elich
  • Publication number: 20220145296
    Abstract: Compositions and methods for binding to a target sequence of interest are provided. Compositions include fusion proteins between DNA binding proteins or protein domains and nucleic acid modifying proteins or protein domains. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, deaminases, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs. Also provided are deaminases which may be fused to a DNA-binding polypeptide and may be useful for gene editing.
    Type: Application
    Filed: December 20, 2019
    Publication date: May 12, 2022
    Applicant: LifeEDIT Therapeutics, Inc.
    Inventors: Tyson D. Bowen, Alexandra Briner Crawley, Tedd D. Elich, Mark Moore, Rodolphe Barrangou, Michael Lassner
  • Publication number: 20220002756
    Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.
    Type: Application
    Filed: September 17, 2021
    Publication date: January 6, 2022
    Applicant: LifeEDIT Therapeutics, Inc.
    Inventors: Alexandra Briner Crawley, Rodolphe Barrangou, Tyson D. Bowen, Michael Coyle, Tedd D. Elich
  • Patent number: 11162114
    Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: November 2, 2021
    Assignee: LifeEDIT Therapeutics, Inc.
    Inventors: Alexandra Briner Crawley, Rodolphe Barrangou, Tyson D. Bowen, Michael Coyle, Tedd D. Elich
  • Publication number: 20190367949
    Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.
    Type: Application
    Filed: June 5, 2019
    Publication date: December 5, 2019
    Applicant: LifeEDIT, Inc.
    Inventors: Alexandra Briner Crawley, Rodolphe Barrangou, Tyson D. Bowen, Michael Coyle, Tedd D. Elich
  • Patent number: 10030248
    Abstract: The present disclosure provides compositions and methods for regulating expression of transcribable polynucleotides in plant cells, plant tissues, and plants. Compositions include regulatory polynucleotide molecules capable of providing expression in plant tissues and plants. Methods for expressing polynucleotides in a plant cell, plant tissue, or plants using the regulatory polynucleotide molecules disclosed herein are also provided.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: July 24, 2018
    Assignee: Monsanto Technology LLC
    Inventors: Tedd D. Elich, Philip N. Benfey, Jee W. Jung
  • Publication number: 20170009248
    Abstract: The present disclosure provides compositions and methods for regulating expression of transcribable polynucleotides in plant cells, plant tissues, and plants. Compositions include regulatory polynucleotide molecules capable of providing expression in plant tissues and plants. Methods for expressing polynucleotides in a plant cell, plant tissue, or plants using the regulatory polynucleotide molecules disclosed herein are also provided.
    Type: Application
    Filed: June 6, 2016
    Publication date: January 12, 2017
    Inventors: Tedd D. Elich, Philip N. Benfey, Jee W. Jung
  • Patent number: 9447423
    Abstract: The present disclosure provides compositions and methods for regulating expression of transcribable polynucleotides in plant cells, plant tissues, and plants. Compositions include regulatory polynucleotide molecules capable of providing expression in plant tissues and plants. Methods for expressing polynucleotides in a plant cell, plant tissue, or plants using the regulatory polynucleotide molecules disclosed herein are also provided.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: September 20, 2016
    Assignee: Monsanto Technology LLC
    Inventors: Tedd D. Elich, Philip N. Benfey, Jee W. Jung